IPlex Approval History 
- FDA approved: Yes (First approved December 12th, 2005)
- Brand name: iPlex
- Generic name: mecasermin rinfabate [rDNA origin]
- Previous name: SomatoKine
- Company: Insmed Incorporated
- Treatment for: Primary IGF-1 Deficiency
iPlex (mecasermin rinfabate) is the human recombinant of the naturally occurring protein complex of insulin-like growth factor-I (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3). iPlex is indicated for the treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.
FDA Approval History for iPlex
See also...
iPlex (mecasermin rinfabate [rDNA origin]) Consumer Information
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
